Focus Partners Wealth Increases Stock Position in IQVIA Holdings Inc. (NYSE:IQV)

Focus Partners Wealth increased its position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 889.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 58,156 shares of the medical research company's stock after acquiring an additional 52,279 shares during the quarter. Focus Partners Wealth's holdings in IQVIA were worth $11,428,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Smith Group Asset Management LLC acquired a new position in shares of IQVIA during the 4th quarter valued at about $1,616,000. Hickory Asset Management Inc. acquired a new position in shares of IQVIA during the 4th quarter valued at about $941,000. Fifth Third Bancorp boosted its position in shares of IQVIA by 13.0% during the 4th quarter. Fifth Third Bancorp now owns 13,179 shares of the medical research company's stock valued at $2,590,000 after acquiring an additional 1,521 shares during the last quarter. Graphene Investments SAS boosted its position in shares of IQVIA by 22.0% during the 4th quarter. Graphene Investments SAS now owns 15,000 shares of the medical research company's stock valued at $2,948,000 after acquiring an additional 2,700 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its holdings in IQVIA by 46.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company's stock valued at $437,378,000 after buying an additional 583,396 shares during the period. Institutional investors and hedge funds own 89.62% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on IQV shares. Mizuho reduced their price objective on shares of IQVIA from $210.00 to $190.00 and set an "outperform" rating on the stock in a report on Thursday. Barclays reduced their price objective on shares of IQVIA from $170.00 to $165.00 and set an "equal weight" rating on the stock in a report on Wednesday, May 7th. HSBC lowered shares of IQVIA from a "buy" rating to a "hold" rating and cut their price target for the stock from $260.00 to $160.00 in a research note on Friday, April 25th. BTIG Research lowered shares of IQVIA from a "buy" rating to a "neutral" rating in a research note on Monday, February 3rd. Finally, Hsbc Global Res lowered shares of IQVIA from a "strong-buy" rating to a "hold" rating in a research note on Friday, April 25th. Eight investment analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $230.76.

IQVIA Stock Up 1.6%

IQVIA stock traded up $2.23 during mid-day trading on Friday, hitting $142.66. The company had a trading volume of 2,227,287 shares, compared to its average volume of 1,514,419. The stock has a market cap of $24.68 billion, a price-to-earnings ratio of 19.02, a PEG ratio of 1.99 and a beta of 1.34. IQVIA Holdings Inc. has a 1 year low of $135.97 and a 1 year high of $252.88. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. The business has a fifty day moving average of $159.83 and a 200 day moving average of $185.72.

IQVIA (NYSE:IQV - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The medical research company reported $2.70 EPS for the quarter, beating the consensus estimate of $2.63 by $0.07. The company had revenue of $3.83 billion for the quarter, compared to analyst estimates of $3.77 billion. IQVIA had a net margin of 8.91% and a return on equity of 28.81%. The firm's revenue was up 2.5% on a year-over-year basis. During the same period in the prior year, the firm posted $2.54 earnings per share. On average, sell-side analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.